Immunexpress Aims To Leverage Anti-Infection Incentives For Sepsis Diagnostic
This article was originally published in Start Up
Executive Summary
Immunexpress' SeptiCyte system is designed to directly quantify molecular markers of sepsis from patient blood samples and within a few hours detect the probability that a patient has sepsis, allowing for aggressive treatment, or if the test result is negative, preventing unnecessary antibiotics.
You may also be interested in...
Battling Infection: Hospitals Seek High-Tech Solutions
The market for diagnostic and infection control products will see continued growth as hospitals and other providers look to the technology sector to help fight the battle against health care-associated infections and antibiotic-resistant organisms.
“Never Events” Spur Medical Device Innovation
Start-ups developing technologies to help hospitals avoid preventable medical errors known as “never events” are developing solutions to nosocomial infections, retained surgical objects, pressure ulcers, and medication errors.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.